StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOKGet Rating) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Shares of NASDAQ EVOK opened at $0.37 on Tuesday. Evoke Pharma has a 1-year low of $0.36 and a 1-year high of $1.81. The business has a 50-day moving average of $0.53 and a 200-day moving average of $0.73. The company has a debt-to-equity ratio of 1.41, a current ratio of 7.51 and a quick ratio of 7.38. The company has a market capitalization of $12.18 million, a price-to-earnings ratio of -1.42 and a beta of 0.77.

Evoke Pharma (NASDAQ:EVOKGet Rating) last issued its earnings results on Tuesday, March 8th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter. Evoke Pharma had a negative return on equity of 154.99% and a negative net margin of 529.48%. The company had revenue of $0.36 million during the quarter.

A number of institutional investors and hedge funds have recently modified their holdings of EVOK. Marshall Wace LLP purchased a new position in Evoke Pharma in the first quarter valued at about $139,000. BlackRock Inc. boosted its holdings in Evoke Pharma by 9.2% in the third quarter. BlackRock Inc. now owns 175,559 shares of the specialty pharmaceutical company’s stock valued at $228,000 after purchasing an additional 14,789 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Evoke Pharma by 19.7% in the third quarter. Geode Capital Management LLC now owns 234,309 shares of the specialty pharmaceutical company’s stock valued at $304,000 after purchasing an additional 38,549 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Evoke Pharma in the fourth quarter valued at about $25,000. Finally, Virtu Financial LLC raised its stake in Evoke Pharma by 192.5% during the fourth quarter. Virtu Financial LLC now owns 55,336 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 36,418 shares in the last quarter. 12.88% of the stock is owned by hedge funds and other institutional investors.

About Evoke Pharma (Get Rating)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.

Read More

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.